NKG2D CAR-NK cell therapy / Hangzhou Cheetah Cell Therap - LARVOL DELTA

NKG2D CAR-NK & Ovarian Cancer (clinicaltrials.gov) - P=N/A | N=18 | Recruiting | Sponsor: Hangzhou Cheetah Cell Therapeutics Co., Ltd

New trial • Oncology • Ovarian Cancer • Solid Tumor

NKG2D CAR-NK Cell for Patients With r/rAML (clinicaltrials.gov) - P=N/A | N=9 | Recruiting | Sponsor: Zhejiang University

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • NKG2D

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P=N/A | N=9 | Terminated | Sponsor: Hangzhou Cheetah Cell Therapeutics Co., Ltd | Phase classification: P1 ➔ P=N/A | Recruiting ➔ Terminated; end

Phase classification • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • NKG2D